spacer
home > ebr > winter 2018 > editorís letter
PUBLICATIONS
European Biopharmaceutical Review

Editorís Letter

This edition of EBR went to press just as a major breakthrough in the development of a potential treatment for Huntingtonís disease was announced by researchers at University College London. Identifying, isolating and then being able to block synthesis of the defective, toxic proteins responsible for disease pathology has taken decades to accomplish, and a number of articles in our current issue resonate with aspects of this journey from gene to treatment. Although the exact neurological role of the Huntingtin gene product is not yet known, it is a complex, highly polymorphic protein and has the ability to identify even subtle changes from a core range of sequences, and structures of biological relevance through functional approaches such as microarrays could become increasingly valuable tools in disease research. The faulty Huntingtin gene responsible for Huntingtonís disease was discovered in 1993.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Dr Deborah OíNeil, Chief Executive and Scientific Officer, NovaBiotics Ltd
spacer
Dr Deborah OíNeil
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Charles River Laboratories Announces Extended Relationship with The Michael J. Fox Foundation

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced an extension of its long-standing collaboration with The Michael J. Fox Foundation for Parkinsonís Research (MJFF), a leading organization working to support the diagnosis and treatment of Parkinsonís disease (PD). Since 2011, Charles River and MJFF have worked together to accelerate the discovery of therapies for PD. This latest extension includes grants from MJFF to support two projects:
More info >>

White Papers

Mouse Models for Evaluation of Vaccines and Therapeutics Against Staphylococcal Infections

IBT Bioservices

Introduction Staphylococcus aureus (SA) is a ubiquitous, formidable Gram-positive pathogen associated with skin and soft tissue, as well as lifethreatening systemic infections. SA is a leading cause of hospital- and community-associated infections worldwide, affecting humans and animals. The wide range of pathologies reflects the diverse abilities of this microbe to escape the innate and adaptive immune response using virulence factors. Since its first emergence in the 1960s methicillin-resistant SA (MRSA) has become endemic in hospitals and healthcare settings worldwide. In the 1990s, community associated MRSA strains (CA-MRSA) emerged, and are spreading worldwide posing a major global challenge.
More info >>

 
Industry Events

Outsourcing in Clinical Trials Medical Device USA 2018

11-12 July 2018, Minneapolis, Minnesota

6th Outsourcing in Clinical Trials conference is the only clinical outsourcing platform for medical device companies within Medical Alley this year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement